ARIES 1 and ARIES 2: Ambrisentan in PAH - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension

Trial Profile

ARIES 1 and ARIES 2: Ambrisentan in PAH - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Pulmonary arterial hypertension; Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms ARIES1; ARIES2
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 30 May 2008 Results published in Circulation.
    • 30 May 2008 Status changed from in progress to completed.
    • 21 May 2008 Results presented at ATS 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top